The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Last post: hxharry, 18 Dec 2020 16:15
$3.93.............58p
Equates to 50p per mph .
Wow $3.50 over on nasdaq
Haha - nice one. I couldn't really understand people were offloading at 25p even on pre close Nasdaq price, but each to their own. I had bought a few more about three weeks ago at 34p and while the rest of my holdings have transferred to ADRs these are still in UK holding. My understanding is that these can still be transferred to ADR on the same basis?
Great news announced after hours. Selling the rights for their rare bone disease (OI) treatment in the US & ROW to a US company, Ultragenyx. They will receive $50m upfront and up to $254m in milestones. Mereo keeping the rights for Europe. Royalties for US & ROW in tier double digit %. Furthermore, Ultragenyx will pay for all the phase 2b/3 trial development. At $3 for the ADR, the stock is only back to the equivalent of c. 45p vs year high of c. 60p so plenty of upside left.
Last post: donmac101, 18 Dec 2020 09:16
Not great for schroders after ditching the rest of their holding. You just gotta smile great move by the board.
Started: rajsa, 24 Nov 2020 09:56
Last post: Sangijuelas1, 2 Dec 2020 15:09
I was told they couldn't by A J Bell, not looking to mislead anyone
I have a holding in a SIPP with Ascentric, they have confirmed that I will be able to convert to ADRs and hold within the SIPP
As a clarification - the ADS can be held in a SIPP but not in an ISA. I checked with HL. Hope that helps.
Mine are held in a SIPP and HL offered me to convert them today. I accepted and got a confirmation. Not sure i need confirmation from a punter on ADVFN that it does not work. maybe HL will change their mind (after reading ADVFN) but at the moment it seems fine. Hopefully the advice/warning was with the best of intentions!
After delisting these shares will only be able to be held in a general dealing account, not an Isa or a Sipp.
See the ADVFN board for confirmation.
Last post: donmac101, 28 Nov 2020 07:01
To many rookies on the market who are clueless ,are going to be burned in the months to come.
Hadn't realised that, @rumbled. I've asked my broker (Charles Stanley) about the transfer but haven't had any reply yet
I think you will find the ratio of the ADS to the common (LSE) share is and always has been 5:1. If you look at the documentation from when the ADS was issued it is clearly stated 5 shares represent 1 ADS. They have not changed this. There is a small amount of arbitrage between the two listings depending on currency etc - no-one is losing given you still have the same shareholding in the company. In simple terms if there were 100 ADS and 1000 (LSE) shares in issue, that would have represented 1,500 (LSE) total shares (1000+(100*5)). Given going forward we can only own ADS there will be (in the example above) 300 ADS instead of 1500 common (LSE) shares (100+(1000/5)). simples.
Thanks Probo...........still mulling it over, seems to be plenty of good news coming but also plenty of risk as always but are you hanging for the NASDAQ conversion Probo?
£0.34 not 0.34p
I think we are seeing the effect of rounding-down to calculate the share allocation, if we assume that the closing prices on the 10th November were used (the day before the de-listing was announced), MPH.L closing was 0.34p = $0.4512 (XR 1.32695), MREO closing was $2.42, so 2.42/0.4512 = 5.3635, rounded down to 5.
So, yes, we are losing approximately 7% of the value of our shares (2.42 - (0.4512 x 5)) / 2.42 * 100 = 6.77) on that date.
All hl punters should have email today to convert .
Started: Jjjerseygirl, 20 Nov 2020 12:59
Last post: Jjjerseygirl, 20 Nov 2020 12:59
Both over :~)
Last post: donmac101, 17 Nov 2020 15:39
This is going to pop when all the punters who are scared of nasdaq listing are out.Lots of news due next few weeks
Started: Sangijuelas1, 14 Nov 2020 12:06
Last post: Sangijuelas1, 14 Nov 2020 12:06
I don't hold this share currently. However, I noticed they are planning to cancel the Aim shares and convert them to ADS. It is worth checking that your broker platform is OK with this. If held in an Isa or a Sipp there are likely to be issues with some service providers. See the Verona Pharma thread as there were issues when they cancelled their Aim shares in favour of ADS
Started: Facevalue01, 25 Aug 2020 21:33
Last post: TribalHound, 11 Nov 2020 18:10
From 8:00am right the way to gone 2pm today - every recorded trade was a Buy (including myself taking advantage of the dip) - and from 2pm to close it was roughly a 50:50 split.
Directors buying with confidence and market activity leaning firmly towards accumulation can only mean that we are early adopters and will be in for a ride.....
Don't loose sight of the fact that MPH only launched on LSE four years ago at mid £2.30's - a tad over 700% rise from todays closing price. Or a 90% drop from ATH circa £3.50 - upside potential is huge - and nobody does upside potential quite like the Pharma sector.
Madness current price equates to 36.8p converted to nasdaq
Big director buy again someones confidant news on the horizon.
Good show of confidence by the Directors buying at this level from the positive RNS release this evening. Hopefully this will help in stopping the slow drift downwards and will give investors a good base to start buying again.
This is the most unexciting share in my portfolio. Except slowly drifting downwards off the back of some small trades it seems to do nothing. Not sure what it will take to wake up and get some momentum.
Started: Jjjerseygirl, 28 Sep 2020 13:05
Last post: Jjjerseygirl, 28 Sep 2020 13:05
Started: scoredagainsteps, 24 Sep 2020 13:07
Last post: Boombaby, 24 Sep 2020 17:25
Very odd. Nothing more to say.
Fake shake, buys showing in red. Strong hold.
Agree!
Nasdaq will love this news.
Gla well pleased
Last post: Boombaby, 24 Sep 2020 14:07
Fake drop looking at bid/sell price at the time of recent trades. Spring coiling IMO. GLA.
On the ask
Some have been spiked
More good news soon i think
Last post: Boombaby, 12 Sep 2020 20:41
Bought in cheap a couple of weeks ago with a note 31/10/2020. End of P3 trial for one of their candidates??
Lots of buying friday
3.04 dollars after hours
Should fly monday
This share is very leaky lol
Last post: Bladey, 25 Aug 2020 13:25
Yes I liked the RNS. Aftercare for a continuing problem with Covid-19. The biggest issue is the attack on the respiratory system of the individual and anything that can help with that particular problem is a sure fire way to treat and mend the patient back to good health.
Mph finally will take part of Covid19
Last post: matarakz, 21 Aug 2020 10:41
Other companies are conducting clinical trial similar to our drug BT 197 -Acumapimod for the treatment of Covid 19 patients. Possible treatment that may enter phase 3 clinical trial. Imho
Started: occams, 18 Aug 2020 16:34
Last post: occams, 18 Aug 2020 16:34
Hoping to provide better therapies for patients with chronically debilitating and life-limiting rare diseases, Mereo Biopharma advances assets from other companies that were not progressed for strategic reasons to late-stage development. Based on its vast potential, some think that its $2.83 share price looks like a steal.
Cohen recently took the opportunity to get in on the action. Reflecting a new position, Point72 bought up 375,000 shares in Q2, with the value of the new holding landing at $1,148,000.
Writing for SVB Leerink, 5-star analyst Joseph Schwartz has high hopes for the company. Along with 2020 fundraising which removed the financial overhang and extended its cash runway into early 2022, he believes the news that etigilimab rejoined the development pipeline will “put this under-the-radar company on the map.”
Etigilimab, which was acquired during MREO's reverse merger with OncoMed back in April, generated encouraging results as both a monotherapy and combination in Phase 1a and Phase 1b, respectively. Based on this data, MREO moved the candidate into a larger Phase 1b trial, which is slated to kick off in Q4 2020. Due to recent developments with other anti-TIGIT programs, the company plans to evaluate multiple tumor types in the Phase 1b trial of etigilimab in combination with an anti-PD1/PDL1.
“We believe MREO’s more deliberate venture into oncology could pay off handsomely for the company: Not only can MREO leverage the previous work and expertise of OncoMed, but investors interested in anti-TIGIT assets could bring new eyes to MREO’s rare disease pipeline which we believe merits a deeper look by the Street,” Schwartz explained.
On top of this, MREO plans to initiate a Phase 3 pediatric study of lead asset setrusumab (anti-sclerostin) for osteogenesis imperfecta (OI) in 2H20, with COVID-19 not expected to cause any delays. Schwartz points out that MREO received positive feedback from a Type B End-of-Phase 2 meeting with the FDA, after encouraging data from setrusumab’s Phase 2b ASTEROID study in adults with OI was released. “While the Phase 3 pediatric study design had prior alignment from the EMA, last month’s announcement removed a significant unknown on the path towards a global pivotal trial for setrusumab,” the analyst noted.
To this end, Schwartz rates MREO an Outperform (i.e. Buy) along with an $8 price target. This target conveys his confidence in MREO’s ability to soar 182% higher in the next twelve months.
Started: Nolupus, 23 Jun 2020 09:10
Last post: occams, 15 Aug 2020 20:40
I think there is some news soon, p33 of presentation, https://www.mereobiopharma.com/media/1465/mereo-corporate-presentation-august-2020.pdf
Seem to have plenty of cash. Cash resources of £16.3 million as at December 31, 2019 (December 31, 2018 £27.5 million). Since the year end, Mereo has raised £60.8 million in Private Placements, £3.8 million from a convertible equity financing and £3.2 million from licensing.
Most people are probably chasing the Covid stocks.
I'm in for 20k shares
Just trying to gauge people's views with this firm. I have invested a small amount here recently looking at their product pipeline for the long term. But noted that it is really quiet with no recent posts, just a few trades, with price slowly drifting down, and spreads showing up at 10%..Is it a function of no news expected? Noted that the cost base is huge, but they do look to have quite a few products in the pipeline,so just trying to figure out why there is lack of interest here.
Nolupus: I think I can better scarper! Only looked at MPH briefly and already the price has dropped nearly 5% !!! Not a good omen, mind you I'm getting very familiar with the colour red now! Definitely prefer blue.
Nolupus....is trading always this quiet on MPH? BTW I'm not stalking you just happen to be travelling in similar cirlcles!!! Waiting for IMM to run!!!
Large trades would suggest positions still being taken.
Once settled can see this moving up gradually with any good news sending this to £1+!
GL.
Last post: Bishop190, 25 Jul 2020 14:20
A restricted link unfortunately.
Bit of action pre market today - +10%, although I've given up trying call this one - just holding and hoping for a break out
Great new appointments and sounds like they mean business!
GL.
Started: petertee, 25 Jun 2020 23:23
Last post: petertee, 25 Jun 2020 23:23
Started: petertee, 25 Jun 2020 16:58
Last post: petertee, 25 Jun 2020 16:58
Chief Executive Officer Denise Scots-Knight said: "We are very pleased with the substantial operational progress we have made throughout 2019 and, particularly, over the past several months."
2019 was a year during which Mereo completed an all-stock merger with OncoMed Pharmaceuticals Inc.
"Successful integration of OncoMed has allowed us to broaden our asset base and significantly strengthen our cash position, enabling us to progress beyond our key clinical milestones," Mereo said.
Started: closettrader, 22 Jun 2020 11:09
Last post: matarakz, 22 Jun 2020 13:07
One of few companies that is undervalued. Mereo has 3 products that already passed phase2 and are phase 3 candidates. Imho, it’ s worth more than a billion pound.
Picked up some this morning, found it difficult to buy from 8.45am to 9.20am ish. But can buy and sell at 48p now.
Have been unable to buy anything over £500 worth all morning......
Started: scoredagainsteps, 17 Jun 2020 09:17
Last post: Nolupus, 17 Jun 2020 10:18
Scored,
Have to keep a close eye on Acacia , imo :-)
500k lots even thou there delayed buys last few days did not hit 43p .. AND a 25/50k buyer imo bottom has been hit
Started: scoredagainsteps, 16 Jun 2020 08:47
Last post: pawnsacrifice, 16 Jun 2020 09:01
Not after cost savings myself just successful products.
Thought this good news all the same..
"Finally, we are now funded into early 2022 providing the Company sufficient balance sheet strength and runway to deliver on our clinical and business development milestones"
or 39p per share well great things going for it but imo to many chiefs -- Always said cash burn here is terrible need to cut costs . DONT get me wrong mereo owes me nothing but i want cost saving